Electrolyte Blood Press.  2015 Dec;13(2):46-51. 10.5049/EBP.2015.13.2.46.

High Water Intake and Progression of Chronic Kidney Diseases

• Choi HY
• Park HC
• Ha SK

• KMID: 2152086
• DOI: http://doi.org/10.5049/EBP.2015.13.2.46

Abstract

Impact of water intake on the courses of chronic kidney and urinary tract diseases, such as urolithiasis, urinary tract infections, chronic kidney diseases (CKD), autosomal dominant polycystic kidney diseases and bladder cancer, has recently been studied. It still remains controversial whether increased water intake slows the progression of CKD or not. However, high water intake suppresses plasma levels of arginine vasopressin (AVP), which is expected to be beneficial for the preservation of the kidney function. Previous studies suggest that water intake suppresses plasma levels of AVP, and high levels of AVP have been suggested to play deleterious roles in animal models of kidney disease. Moreover, recent epidemic of CKD of unknown origin, which was supposed to be related to the insufficient water intake and chronic volume depletion, has been reported in Central America, further suggesting that the suppression of AVP by sustained water intake might be beneficial in this CKD population. Indeed, the data from recent studies were consistent with the view that high water intake is associated with slower progression of CKD. However, contradictory findings also exist. The intriguing effects of increased urine volume in preserving the glomerular filtration rate in human patients with CKD require more large and well-designed randomized prospective clinical trials.

Keyword

Water; Intake; Hydration; Dehydration; Progression; Chronic kidney disease

MeSH Terms

Arginine Vasopressin
Central America
Dehydration
Drinking*
Glomerular Filtration Rate
Humans
Kidney
Kidney Diseases
Models, Animal
Plasma
Polycystic Kidney, Autosomal Dominant
Prospective Studies
Renal Insufficiency, Chronic*
Urinary Bladder Neoplasms
Urinary Tract Infections
Urolithiasis
Urologic Diseases
Water*
Arginine Vasopressin
Water

Reference

1. Lotan Y, Daudon M, Bruyere F, Talaska G, Strippoli G, Johnson RJ, et al. Impact of fluid intake in the prevention of urinary system diseases: a brief review. Curr Opin Nephrol Hypertens. 2013; 22(Suppl 1):S1–S10. PMID: 23673384.

2. Fitzsimons JT. The physiological basis of thirst. Kidney Int. 1976; 10:3–11. PMID: 781378.

3. Knepper MA, Kwon TH, Nielsen S. Molecular Physiology of Water Balance. N Engl J Med. 2015; 373:196. PMID: 26154805.

4. Zerbe RL, Robertson GL. Osmoregulation of thirst and vasopressin secretion in human subjects: effect of various solutes. Am J Physiol. 1983; 244:E607–E614. PMID: 6407333.

5. Sagawa S, Miki K, Tajima F, Tanaka H, Choi JK, Keil LC, et al. Effect of dehydration on thirst and drinking during immersion in men. J Appl Physiol (1985). 1992; 72:128–134. PMID: 1531647.

6. Robertson GL, Shelton RL, Athar S. The osmoregulation of vasopressin. Kidney Int. 1976; 10:25–37. PMID: 181630.

7. M W. Phenomenological analysis of electrolyte and water homeostasis. New York: Raven Press;1985. p. 3–13.

8. Popkin BM, D'Anci KE, Rosenberg IH. Water, hydration, and health. Nutr Rev. 2010; 68:439–458. PMID: 20646222.

9. Schoen EJ. Minimum urine total solute concentration in response to water loading in normal men. J Appl Physiol. 1957; 10:267–270. PMID: 13428657.

10. Kwon TH, Nielsen J, Moller HB, Fenton RA, Nielsen S, Frokiaer J. Aquaporins in the kidney. Handb Exp Pharmacol. 2009; DOI: 10.1007/978-3-540-79885-9_5.95-132.

11. Robertson GL, Athar S. The interaction of blood osmolality and blood volume in regulating plasma vasopressin in man. J Clin Endocrinol Metab. 1976; 42:613–620. PMID: 1262438.

12. Knepper MA, Star RA. Vasopressin: friend or foe? Nat Med. 2008; 14:14–16. PMID: 18180711.

13. Mutig K, Paliege A, Kahl T, Jons T, Muller-Esterl W, Bachmann S. Vasopressin V2 receptor expression along rat, mouse, and human renal epithelia with focus on TAL. Am J Physiol Renal Physiol. 2007; 293:F1166–F1177. PMID: 17626156.

14. Knepper MA, Nielsen S, Chou CL, DiGiovanni SR. Mechanism of vasopressin action in the renal collecting duct. Semin Nephrol. 1994; 14:302–321. PMID: 7938946.

15. Knepper MA. Systems biology in physiology: the vasopressin signaling network in kidney. Am J Physiol Cell Physiol. 2012; 303:C1115–C1124. PMID: 22932685.

16. Bankir L. Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptormediated effects. Cardiovasc Res. 2001; 51:372–390. PMID: 11476728.

17. Nielsen S, Frokiaer J, Marples D, Kwon TH, Agre P, Knepper MA. Aquaporins in the kidney: from molecules to medicine. Physiol Rev. 2002; 82:205–244. PMID: 11773613.

18. Kwon TH, Frokiaer J, Knepper MA, Nielsen S. Reduced AQP1, -2, and -3 levels in kidneys of rats with CRF induced by surgical reduction in renal mass. Am J Physiol. 1998; 275:F724–F741. PMID: 9815130.

19. Aoyagi T, Izumi Y, Hiroyama M, Matsuzaki T, Yasuoka Y, Sanbe A, et al. Vasopressin regulates the renin-angiotensin-aldosterone system via V1a receptors in macula densa cells. Am J Physiol Renal Physiol. 2008; 295:F100–F107. PMID: 18448596.

20. Teitelbaum I, McGuinness S. Vasopressin resistance in chronic renal failure. Evidence for the role of decreased V2 receptor mRNA. J Clin Invest. 1995; 96:378–385. PMID: 7615808.

21. Bouby N, Fernandes S. Mild dehydration, vasopressin and the kidney: animal and human studies. Eur J Clin Nutr. 2003; 57(Suppl 2):S39–S46. PMID: 14681712.

22. Bouby N, Bachmann S, Bichet D, Bankir L. Effect of water intake on the progression of chronic renal failure in the 5/6 nephrectomized rat. Am J Physiol. 1990; 258:F973–F979. PMID: 2184677.

23. Sugiura T, Yamauchi A, Kitamura H, Matsuoka Y, Horio M, Imai E, et al. High water intake ameliorates tubulointerstitial injury in rats with subtotal nephrectomy: possible role of TGF-beta. Kidney Int. 1999; 55:1800–1810. PMID: 10231442.

24. Bouby N, Hassler C, Bankir L. Contribution of vasopressin to progression of chronic renal failure: study in Brattleboro rats. Life Sci. 1999; 65:991–1004. PMID: 10499867.

25. Naito A, Hasegawa H, Kurasawa T, Ohtake Y, Matsukawa H, Ezure Y, et al. Histopathological study of kidney abnormalities in an experimental SIADH rat model and its application to the evaluation of the pharmacologic profile of VP-343, a selective vasopressin V2 receptor antagonist. Biol Pharm Bull. 2001; 24:897–901. PMID: 11510481.

26. Correa-Rotter R, Wesseling C, Johnson RJ. CKD of unknown origin in Central America: the case for a Mesoamerican nephropathy. Am J Kidney Dis. 2014; 63:506–520. PMID: 24412050.

27. Clark WF, Sontrop JM, Macnab JJ, Suri RS, Moist L, Salvadori M, et al. Urine volume and change in estimated GFR in a community-based cohort study. Clin J Am Soc Nephrol. 2011; 6:2634–2641. PMID: 21885793.

28. Strippoli GF, Craig JC, Rochtchina E, Flood VM, Wang JJ, Mitchell P. Fluid and nutrient intake and risk of chronic kidney disease. Nephrology (Carlton). 2011; 16:326–334. PMID: 21342326.

29. Sontrop JM, Dixon SN, Garg AX, Buendia-Jimenez I, Dohein O, Huang SH, et al. Association between water intake, chronic kidney disease, and cardiovascular disease: a cross-sectional analysis of NHANES data. Am J Nephrol. 2013; 37:434–442. PMID: 23594828.

30. Clark WF, Sontrop JM, Huang SH, Gallo K, Moist L, House AA, et al. : The chronic kidney disease Water Intake Trial (WIT): results from the pilot randomised controlled trial. BMJ Open. 2013; 3:e003666.

31. Hebert LA, Greene T, Levey A, Falkenhain ME, Klahr S. High urine volume and low urine osmolality are risk factors for faster progression of renal disease. Am J Kidney Dis. 2003; 41:962–971. PMID: 12722030.

32. Magpantay L, Ziai F, Oberbauer R, Haas M. The effect of fluid intake on chronic kidney transplant failure: a pilot study. J Ren Nutr. 2011; 21:499–505. PMID: 21620725.

33. Sontrop JM, Huang SH, Garg AX, Moist L, House AA, Gallo K, et al. Effect of increased water intake on plasma copeptin in patients with chronic kidney disease: results from a pilot randomised controlled trial. BMJ Open. 2015; 5:e008634.